Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	123558
DOI	10.4251/wjgo.123558
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Resveratrol suppresses ulcerative colitis and colitis-associated colorectal cancer via modulating the miR-31-5p/SATB2 axis
Manuscript Source	Unsolicited Manuscript
All Author List	Ya-Li Wu, Xi Wang, Xin-Xin Du, Kai-Li Liu, Chun-Fang Wang, Jin-Chun Liu, Ji-Min Cao and Xiang-Li Cui
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81272695
Corresponding Author	Xiang-Li Cui, Full Professor, PhD, MOE Key Laboratory of Cellular Physiology, and Department of Physiology, Shanxi Medical University, No. 56 Xinjian South Road, Yingze District, Taiyuan 030001, Shanxi Province, China. cuixiangli@163.com
Key Words	MiR-31-5p; Special AT-rich sequence-binding protein 2; Ulcerative colitis; Colitis-associated cancer; Azoxymethane; Dextran sulphate sodium; Resveratrol
Core Tip	By integrating the microRNA sequencing data of human colorectal cancer from The Cancer Genome Atlas and the transcriptomic data from a small human ulcerative colitis (UC) cohort, we provisionally identify that miR-31-5p promotes the colonic inflammation-to-cancer transition. MiR-31-5p exacerbates dextran sulfate sodium-induced colitis and its transition to colitis-associated colorectal cancer (CAC) by targeting special AT-rich sequence-binding protein 2. The miR-31-5p/special AT-rich sequence-binding protein 2 axis is found to modulate Toll-like receptor-4/nuclear factor-κB and apoptosis pathways, revealing a key molecular link in UC-to-CAC transition. Resveratrol, a small plant-derived compound, ameliorates bowel inflammation and inhibits UC progression to CAC via this axis in mice in vivo. The study provides mechanistic insights into the UC-to-CAC progression and highlights the therapeutic potential of resveratrol for the diseases.
Citation	Wu YL, Wang X, Du XX, Liu KL, Wang CF, Liu JC, Cao JM, Cui XL. Resveratrol suppresses ulcerative colitis and colitis-associated colorectal cancer via modulating the miR-31-5p/SATB2 axis. World J Gastrointest Oncol 2026; In press DOI: https://doi.org/10.4251/wjgo.123558
PDF	123558-in-press.pdf

Received	2026-05-22 06:42
Peer-Review Started	2026-05-22 06:42
First Decision by Editorial Office Director
Return for Revision	2026-07-01 03:17
Revised	2026-07-13 15:39
Publication Fee Transferred	2026-07-30 04:55
Second Decision by Editor	2026-09-14 03:05
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-09-15 09:27
Articles in Press	2026-09-15 09:27
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com